bay-44-4400 has been researched along with Intestinal-Diseases--Parasitic* in 3 studies
2 trial(s) available for bay-44-4400 and Intestinal-Diseases--Parasitic
Article | Year |
---|---|
Safety of concurrent treatment of cats with fluralaner and emodepsid-praziquantel.
Fluralaner is a novel systemic ectoparasiticide for cats providing immediate and persistent flea- and tick-control after a single topical dose. Emodepsid and praziquantel are routinely used to control intestinal worm infections in cats. The safety of concurrent use of fluralaner and a commercially available emodepsid-praziquantel combination topical solution was investigated using topical administrations at the maximum recommended dose rates.. Few mild and transient clinical findings like erythema at the administration site and single incidences of salivation or vomiting were observed. All of which were consistent with the individual product leaflets. There were no findings suggesting an increased safety risk associated with the concurrent treatment of cats with fluralaner and emodepsid-praziquantel.. Concurrent treatment with fluralaner, emodepsid and praziquantel is well tolerated in cats. Topics: Animals; Anthelmintics; Cat Diseases; Cats; Depsipeptides; Dermatitis, Contact; Drug Interactions; Drug Therapy, Combination; Ectoparasitic Infestations; Erythema; Female; Insecticides; Intestinal Diseases, Parasitic; Isoxazoles; Male; Praziquantel; Salivation | 2016 |
Efficacy of emodepside/toltrazuril suspension (Procox® oral suspension for dogs) against mixed experimental Isospora felis/Isospora rivolta infection in cats.
The coccidia Isospora felis and Isospora rivolta are intestinal parasites occurring worldwide in domestic cats. In young cats, they can be detected with higher prevalence.The effects of toltrazuril in the new combination product Procox(®) oral suspension for dogs containing 0.1 % emodepside and 2 % toltrazuril (0.9 mg emodepside + 18 mg toltrazuril per ml) were studied in eighteen kittens experimentally infected each with a total of 1 x 10(5) oocysts of a mixture of Isospora felis and Isospora rivolta. In the infectious material, the quantitative relation of I. felis and I. rivolta was about 1:5. Following a three-days period after infection, two groups of 6 kittens were treated during the prepatent period with either a single dose of 0.45 mg emodepside + 9 mg toltrazuril/kg body weight or 0.9 mg emodepside + 18 mg toltrazuril/kg body weight. A group of six kittens without any treatment served as a control. On day 5 post infection, the untreated kittens started the excretion of oocysts. Treatment with both toltrazuril doses significantly reduced oocyst excretion. Following the single higher dose, the reduction of oocysts of both Isospora spp. was more pronounced (96.7 % to 100 %) in comparison to the lower dose (57.2 % to 100 %). The Procox(®) application was well tolerated and no adverse events were seen with any of the applied dosages.When administered to kittens and as a single treatment during the prepatent period, Procox(®) is suitable to control the number of oocysts excreted in the faeces in case of an Isospora felis and Isospora rivolta infection. Topics: Administration, Oral; Animals; Cat Diseases; Cats; Coccidiostats; Depsipeptides; Diarrhea; Drug Combinations; Drug Evaluation; Intestinal Diseases, Parasitic; Isospora; Isosporiasis; Triazines | 2011 |
1 other study(ies) available for bay-44-4400 and Intestinal-Diseases--Parasitic
Article | Year |
---|---|
Gastrointestinal Parasite Infection in Cats in Daegu, Republic of Korea, and Efficacy of Treatment Using Topical Emodepside/Praziquantel Formulation.
The purpose of this study was 2-fold: 1) to investigate the prevalence of gastrointestinal parasite infection in cats reared in Daegu, Republic of Korea and 2) to assess the efficacy and safety of a topical emodepside/praziquantel formulation for cats with parasitic infections. The gastrointestinal parasite infections were examined microscopically using the flotation method. Of 407 cats, 162 (39.8%) were infected by at least one gastrointestinal parasite, including Toxocara cati (63.0%), Toxascaris leonina (31.5%), Taenia taeniaeformis (3.7%), and Cystoisospora felis (1.9%). None of the infected animals had multiple infections. When the data were analyzed according to sex, age, and type of cat, stray cats showed statistically higher prevalence than companion cats (P<0.05). On the 5th day after treatment, no parasitic eggs were detected using microscopic examination. In addition, no adverse effects, such as abnormal behaviors and clinical symptoms, were observed in the cats treated with the drug. These results quantify the prevalence of gastrointestinal parasites in cats in Daegu, Republic of Korea, and show that topical emodepside/praziquantel is a safe and effective choice for treating the parasitic infections in cats. Topics: Animals; Anthelmintics; Cat Diseases; Cats; Depsipeptides; Drug Compounding; Drug Therapy, Combination; Female; Gastrointestinal Tract; Intestinal Diseases, Parasitic; Male; Praziquantel; Republic of Korea; Taenia; Toxascaris; Toxocara | 2019 |